

Amendments to the Specification:

Please amend the specification on page 10 by replacing paragraph 30 with the following replacement paragraph:

Figure 3 is a schematic representation of a MTS molecule having features of the invention in which a cargo portion C is a contrast agent or drug, a basic portion B is a sequence of eight to ten D-arginine residues (e.g., rrrrrrr (SEQ ID NO: 4)), a linker portion X is a cleavable linker that may be cleaved by proteolytic enzymes or reducing environment found near cancerous cells, and an acidic portion A is an inhibitory domain comprising D-amino acids.

Please amend the specification on page 33, line 5 by replacing paragraph 92 (pages 32-33) with the following replacement paragraph:

A number of peptides whose cell uptake could be modulated were synthesized. In the following, the following symbols, where used, are used with the indicated meanings: Fl = fluorescein; aca = aminocaproic acid linker (-HN-(CH₂)₅-CO-), C = L-cysteine, E = L-glutamate, R = L-arginine, D = L-aspartate, K = L-lysine, A = L-alanine, r = D-arginine, c = D-cysteine, e = D-glutamate, P = L-proline, L = L-leucine, G = glycine, V = valine, I = isoleucine, M = methionine, F = phenylalanine, Y = tyrosine, W = tryptophan, H = histidine, Q = glutamine, N = arginine asparagine, S = serine, and T = threonine. In sequences discussed below, lower case letters indicate the D isomer of the amino acid.